TD Cowen analyst Tyler Van Buren has maintained their bullish stance on OLMA stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tyler Van Buren has given his Buy rating due to a combination of factors tied to Olema’s lead asset palazestrant and its late-stage development path. He highlights that Phase II results in metastatic breast cancer showed a notably longer median progression-free survival than what is expected for standard endocrine therapy in the upcoming Phase III OPERA-01 trial, supporting a strong likelihood of positive data in the fall.
In addition, he notes that key opinion leaders and surveyed physicians view palazestrant as potentially best-in-class if it delivers a hazard ratio at or below 0.5 in ESR1‑mutant disease, with even modest efficacy in wildtype patients likely to drive broad uptake. Van Buren also points to palazestrant’s perceived advantages in safety and combinability, plus the forthcoming first‑in‑human KAT6 inhibitor data, as reinforcing confidence in Olema’s differentiated pipeline and long‑term value creation potential.
Van Buren covers the Healthcare sector, focusing on stocks such as Moderna, Gilead Sciences, and BridgeBio Pharma. According to TipRanks, Van Buren has an average return of 20.6% and a 53.93% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $38.00 price target.